SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Cambridge Material Testing Solutions

19 Jun 2018 07:00

RNS Number : 7039R
Frontier IP Group plc
19 June 2018
 

RNS REACH / RNS

AIM: FIPP

19th June 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - New Portfolio Company, Cambridge Material Testing Solutions

 

 

Frontier IP, which specialises in commercialising university intellectual property, today announces it has taken a 24 per cent stake in Cambridge Material Testing Solutions ("the Company"), a business established to support the work of Dr James Dean, an expert in the mechanics and deformation of materials.

 

The Company is developing software and hardware to measure material characteristics in critical metal components more swiftly, cost effectively, and accurately than other systems. Among other potential benefits is mobile and remote testing on site, and the ability to assess complex components and joints.

 

The technology has a very wide range of applications in several sectors, including in the aerospace, nuclear, and oil and gas industries where material degradation and component life assessment of high value assets is critically important.

 

Currently, the hardware used to measure material characteristics forces a hard tip into a metal surface to create an indent. The material response characteristics are measured, allowing simple measurements of hardness and stiffness to be made. Existing indentation test equipment is bulky and laboratory based.

 

Cambridge Material Testing Solutions is addressing the materials testing challenges facing industry by focusing on two development areas:

 

o a suite of software tools, called SEMPID. This can process data generated by existing indentation test equipment and swiftly convert it into information easily understood by engineers to assess the strength and remaining working life of metal components;

 

o customised indentation test equipment. The new systems will be desktop-based, mobile, or fixed on site to assess critical components while in service.

 

Dr James Dean received his PhD from the Department of Materials Science at the University of Cambridge. He has worked for Frazer Nash Consultancy, a leading systems and engineering technology company, on a number of projects, mainly in the nuclear and aerospace industries. He then joined Double Precision Consultancy, a specialist in tackling complex engineering challenges.

 

 

More details about the technology are below.

 

Frontier IP Chief Executive Officer Neil Crabb said: "Frontier IP is delighted to be working with Dr. James Dean and his team to help accelerate the commercialisation of this exciting technology. We believe Cambridge Material Testing Solutions could prove invaluable to companies in critical sectors which need to ensure the materials they use are safe and robust."

 

Cambridge Material Testing Solutions' Chief Technology Officer, Dr. James Dean said: "Our partnership with Frontier IP is further confirmation of our proposition's value. With Frontier IP's expertise in the commercialisation of advanced technologies and its ready access to the sectors we intend to penetrate, where the accurate and non-destructive characterisation of material properties is crucial to the safe operation of high value assets."

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

 

About the Cambridge Materials Testing Solutions technology:

The Company is initially developing a suite of user-friendly software packages that allow rapid and accurate evaluation of the parameters that characterise mechanical properties (such as yield stress and work hardening rate) from instrumented indentation tests. These non-destructive tests are quick and easy to carry out.

 

Another major attraction is that such experiments require only small samples of simple shape (such as plates of mm dimensions), while mapping of local properties over the surface of larger samples is also possible.

 

The suite of software packages, called SEMPID (Software for the Extraction of Material Properties from Indentation Data), are application specific tools for converting indentation data into mechanical material parameters and stress-strain curves.

 

An application for the calculation of stress-strain curves (plasticity parameters) is already available in beta version. This application can process data generated during an indentation test (load-displacement curves or residual indent shapes) and swiftly convert it into stress-strain data that can subsequently be used to assess the strength and remaining working life of metal components.

 

Their software solutions can significantly reduce materials testing turnaround times and materials testing costs.

 

In addition, and as part of their proposed portfolio of materials testing solutions, the Company is developing a customised suite of indentation test equipment including a bespoke desktop-based indenter, and a portable indenter for remote testing of in-service and on-site components.

 

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income from by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRASFESUAFASELM
Date   Source Headline
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.